Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sibutramine Clear all
Completed Not applicable Interventional

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

NCT00037752
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity
Interventions
Sibutramine, Behavioral Smoking Cessation Program
Drug · Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 19, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
View directory record Official record
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 19, 2026, 10:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

NCT01023139
View directory record Official record
Conditions
Obesity
Interventions
Sibutramine
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 19, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Studying the Effects of Sibutramine on Eating Behavior

NCT01170364
View directory record Official record
Conditions
Obesity
Interventions
Sibutramine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Binge Eating in Obese Patients in Primary Care

NCT00537810
View directory record Official record
Conditions
Obesity, Binge Eating
Interventions
Sibutramine, Placebo, Self-help CBT + Sibutramine, Self-help CBT + Placebo
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420
View directory record Official record
Conditions
Obesity
Interventions
Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 2Phase 3 Interventional

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598, sibutramine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
15
States / cities
Clearwater, Florida • Kissimmee, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

NCT00234832
View directory record Official record
Conditions
Obesity
Interventions
Sibutramine hydrochloride, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
55 Years and older
Enrollment
10,777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2010 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

NCT00829283
View directory record Official record
Conditions
Obesity, Binge Eating
Interventions
Behavioral Weight Loss, Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy, Placebo, Sibutramine/Orlistat
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 19, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

A Weight Loss Study in Overweight Men and Women

NCT00993421
View directory record Official record
Conditions
Obesity
Interventions
LY377604, Sibutramine, Metoprolol, Placebo sibutramine, Placebo Metoprolol, Placebo LY377604
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Mesa, Arizona • Concord, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Sibutramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
16
States / cities
El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

NCT00433641
View directory record Official record
Conditions
Obesity
Interventions
sibutramine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

NCT00234988
View directory record Official record
Conditions
Obesity
Interventions
sibutramine hydochloride monohydrate
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Oct 19, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity

NCT00330525
View directory record Official record
Conditions
Obesity, Overweight
Interventions
sibutramine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 19, 2026, 10:58 AM EDT